ArticleResearch and practice in thrombosis and haemostasis2026
Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Monitoring patients with severe hemophilia A (SHA) receiving nonfactor replacement therapies such as emicizumab presents significant challenges, because conventional activated partial thromboplastin time-based assays are subject to interference from these treatments. Therefore, we hypothesized that an intrinsic activated thrombin generation assay (TGA) could be an improved alternative. Objectives: To investigate the sensitivity and applicability of intrinsic activated TGA compared with extrinsic activated assays for monitoring SHA patients on factor (F)VIII (FVIII) and non-FVIII replacement products. Methods: We developed a novel intrinsic trigger reagent (platelet-poor plasma [PPP] Reagent INT) and compared it with tissue factor (TF) reagents, as well as an FXIa-based reagent, using the Calibrated Automated Thrombography method. Thrombin generation was measured in deficient plasmas, healthy volunteers ( Results: PPP Reagent INT specifically activated the intrinsic pathway, showing minimal thrombin generation in FXII- and FXI-deficient plasma, and no thrombin generation in FIX- and FVIII-deficient plasma, whereas activation occurred independently of prekallikrein. Linear regression analysis showed superior sensitivity for PPP Reagent INT triggered thrombin generation in FVIII-deficient plasma spiked with octocog alfa or emicizumab. In plasma from SHA patients, PPP Reagent INT demonstrated sixfold and fourfold greater sensitivity to emicizumab level changes compared with TF-based reagents. Conclusion: Intrinsic activated TGA using PPP Reagent INT provides enhanced sensitivity for monitoring SHA patients on both FVIII and non-FVIII replacement products compared with TF-based triggers, representing a promising tool for personalized monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.